Abstract:【Objective】 To evaluate the effect of gonadotropin releasing hormone agonist (GnRHa) combined with kuntai capsule on the sex hormone and humoral immunity of endometriosis patients. 【Methods】 A total of 150 patients with endometriosis in our hospital from April 2015 to February 2017 were selected and randomly divided into two groups: the control group (75 cases) and the observation group (75 cases). The control group was treated with GnRHa, and the observation group was treated with Kuntai capsule on the basis of the control group. The changes of sex hormones, humoral immunity index, Kupperman score and bone mineral density before and after treatment were compared between the two groups, and the clinical efficacy and medication safety of the two groups were evaluated.【Results】 The total effective rate of the observation group was 90.67% (68/75), which was significantly higher than that of the control group 70.67% (53/75). The adverse reaction rate of the observation group was 5.33% (4/75),which was lower than that of the control group of 16.00% (12/75). The difference was statistically significant (P<0.05). After treatment, the levels of serum estradiol (E2), follicle stimulating hormone (FSH), luteinizing hormone (LH), complement 3 and 4 (C3 and C4) in the observation group were lower than those in the control group; the difference were statistically significant (P<0.05). There were no statistically significant differences in serum immunoglobulin G (IgG), IgM and bone density between the two groups before and after treatment (P>0.05). After treatment, the C4 levels and complement were lower than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the Kupperman score in the observation group was lower than that in the control group; and the differences were statistically significant (P<0.05). 【Conclusion】 The treatment of GnRHa combined Kuntai capsule for endometriosis patients has better curative effect. It can adjust body sex hormone levels, improve humoral immune function, and alleviate or eliminate clinical symptoms with medication safety.
[1] 马跃凤,蒋学禄.子宫内膜异位症早期诊断研究进展[J].浙江临床医学,2016,18(5):960-962. [2] 赖金英.中药口服加灌肠治疗子宫内膜异位症45例疗效观察[J].中国中医药科技,2016,23(1):111-112. [3] Kim B,Yoo JY,Kim TH,et al.Aberrant activation of signal transducer and activator of transcription-3 (STAT3) signaling in endometriosis[J].Hum Reprod,2015,30(5):1069-1078. [4] 赵玲娟,孔方方,邵艳社.子宫内膜异位症中西医治疗进展[J].解放军医药杂志,2015,27(6):114-116. [5] 中华医学会妇产科学分会子宫内膜异位症协作组.子宫内膜异位症的诊治指南[J].中华妇产科杂志,2015,50(3):161-169. [6] 张小春.坤泰胶囊联合炔雌醇环丙孕酮片治疗多囊卵巢综合征的临床效果[J].中国当代医药,2016,23(29):88-90. [7] Zung A, Burundukov E,Ulman M, et al.Monitoring gonadotropin-releasing hormone analogue (GnRHa) treatment in girls with central precocious puberty: a comparison of four methods[J].J Pediatr Endocrinol Metab,2015,28(7-8):885-893. [8] 陆海英.孕三烯酮治疗子宫内膜异位症对患者血清 FSH、E2、LH 及 PROG 的影响[J].河北医药,2016,38(7):1021-1023. [9] 钱雅丽,史慧星,张永存.HIFU联合GnRHa治疗子宫腺肌病的疗效[J].热带医学杂志,2016,16(5):618-621. [10] 李国华,王凤卿,李晓芳,等.GnRHa联合左炔诺孕酮宫内缓释系统治疗大子宫腺肌病的疗效观察[J].国际妇产科学杂志,2016,43(5):594-597. [11] 王秋香,徐晓娟,姚莉娟,等.从“肾虚血瘀”论治子宫内膜异位症并发不孕[J].成都中医药大学学报,2015,38(2):105-108.